Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.65 |
| ▸ | NPC1 | O15118 | 10/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.65 |
| ▸ | MEN1 | O00255 | 7/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.62 |
| ▸ | RELA | Q04206 | 3/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.62 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | CASP2 | P42575 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12963106 | 0.88 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL12932850 | 0.84 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1307056 | 0.84 | MAPT (0.82) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL9776965 | 0.83 | DYRK1A (0.65) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL21814758 | 0.83 | QPCT (0.63) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL10531721 | 0.83 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8280120 | 0.83 | NPC1 (0.70) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL17131947 | 0.82 | RAB9A (0.76) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL27815206 | 0.82 | RAB9A (0.81) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2114859 | 0.81 | NPC1 (0.68) | RAB9ANPC1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20080125399-A1 | 17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2008-05-29 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| WO-2005030704-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| WO-2004069823-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2004-08-19 | — | — | WO | disclosed |
| WO-2003024448-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | RAB9A 3036/4885NPC1 1293/4885SMN1; SMN2 3557/4885 |
| US-20080125399-A1 | 17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators | AR, CYP17A1, SHBG | RAB9A 4368/4885NPC1 3145/4885SMN1; SMN2 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.